Research & Development
Recordati continuously develops new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes.
Commitment, scientific rigour, capability and highly specialized personnel allow the Group to develop new treatments and to build an innovative product pipeline.
Life Cycle Management

New Products

Post Marketing


In addition to the above, RRD is conduding Rollover studies for Signifor and Isturisa as well as several safety commitments, among which
PASS for Cystadrops, Isturisa, Signifor, Qarziba, and Carbaglu PA/MMA, iMO (Castleman’s Disease) Registries
NAME
|
ORIGINATOR
|
INDICATION
|
DEVELOPMENT STATUS
|
---|---|---|---|
ELIGARD®
|
Tolmar
|
Hormone-dependent prostate cancer
|
New device post-approval activities
|
ISTURISA®
|
Novartis
|
Endogenous Cushing’s syndrome/Cushing’s disease
|
Approved in the USA, Europe, Switzerland, Australia, Israel and Japan. Filed in other countries
|
SIGNIFOR®
|
Novartis
|
Pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
|
Phase II in progress
|
CYSTADROPS®
|
Recordati
|
Corneal cystine crystal deposits in patients with cystinosis
|
Approved in the USA and Europe. Development of new formulations in the USA and EU
|
QARZIBA®
|
Apeiron/Recordati
|
Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma
|
Approved in the EU, UK, Australia, Brazil, China Hong Kong, Israel, Russia and Taiwan. Under development for registration in other territories, including USA and Switzerland
|
SYLVANT®
|
Recordati
|
Treatment of idiopathic Multicentric Castleman Disease (iMCD)
|
Approved in over 40 countries including EU, US and China. Potential indication expansion evaluation ongoing
|
REC 0559
|
Recordati/M1meTech
|
Neurotrophic keratitis
|
Phase 2 in progress
|
REC 0545
|
Recordati/AP-HP
|
Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosis
|
Filing expected in 2023
|
CARBAGLU®
|
(Recordati RareDiseases)
|
Hyperammonaemia due to NAGS deficiency and to the main organic acidaemias
|
Regulatory procedure ongoing in China for approval in NAGS deficiency and organic acidaemias
|
REAGILA®
|
Gedeon Richter
|
Schizophrenia
|
Paediatric post-approval development plan
|
We are uniquely structured with multiple opportunities across our R&D team including CMC, preclinical, regulatory, patient safety, QA, clinical operations, clinical development, medical affairs. We are continuously growing, with a focus on developing new specialties, new treatments – and investing in medical innovations that bring a brighter future.
Interested in joining our team?
We foster an entrepreneurial environment where high-performing individuals are empowered to make a difference across our organisation.